Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$7.23 +1.7%	$6.30	$3.93 ▼ $7.54	$364.59M	1.55	710,270 shs	850,820 shs
ALDX Aldeyra Therapeutics	$5.81 -1.2%	$4.70	$1.14 ▼ $7.20	$352.19M	0.76	981,050 shs	1.03 million shs
MIST Milestone Pharmaceuticals	$1.70 -0.6%	$1.71	$0.63 ▼ $2.75	$145.34M	0.52	925,685 shs	761,130 shs
OLMA Olema Pharmaceuticals	$5.76 +4.0%	$4.79	$2.86 ▼ $13.93	$380.23M	1.92	535,497 shs	432,641 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	+1.57%	-1.66%	+9.05%	+10.75%	+35.69%
ALDX Aldeyra Therapeutics	+4.44%	+10.94%	+9.70%	+164.86%	+9.70%
MIST Milestone Pharmaceuticals	+4.27%	+1.79%	+11.04%	+11.04%	+22.14%
OLMA Olema Pharmaceuticals	+1.65%	+5.32%	+22.03%	+9.92%	-55.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABEO Abeona Therapeutics	4.4467 of 5 stars	3.5	2.0	4.5	2.5	2.5	1.3
ALDX Aldeyra Therapeutics	2.1231 of 5 stars	3.3	1.0	0.0	2.5	1.7	0.6
MIST Milestone Pharmaceuticals	1.4006 of 5 stars	3.1	1.0	0.0	0.9	2.5	0.0
OLMA Olema Pharmaceuticals	1.7976 of 5 stars	3.3	0.0	0.0	2.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	3.00	Buy	$19.50	169.71% Upside
ALDX Aldeyra Therapeutics	2.67	Moderate Buy	$9.50	63.51% Upside
MIST Milestone Pharmaceuticals	2.25	Hold	$5.00	194.12% Upside
OLMA Olema Pharmaceuticals	2.67	Moderate Buy	$24.00	316.67% Upside

Current Analyst Ratings Breakdown

Latest MIST, ABEO, OLMA, and ALDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/15/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$19.00 ➝ $20.00
8/14/2025	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$28.00 ➝ $29.00
8/12/2025	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $21.00
8/11/2025	OLMA Olema Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/8/2025	ALDX Aldeyra Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/14/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/5/2025	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$5.00
6/2/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$19.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$3.50M	105.93	N/A	N/A	$3.19 per share	2.27
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.92 per share	N/A
MIST Milestone Pharmaceuticals	$1M	144.48	N/A	N/A	($0.21) per share	-8.10
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.03 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	-$63.73M	$0.70	10.33	N/A	N/A	N/A	89.05%	45.64%	N/A
ALDX Aldeyra Therapeutics	-$55.85M	-$0.85	N/A	N/A	N/A	N/A	-73.63%	-50.61%	11/6/2025 (Estimated)
MIST Milestone Pharmaceuticals	-$41.52M	-$0.84	N/A	N/A	N/A	N/A	-1,672.29%	-83.09%	N/A
OLMA Olema Pharmaceuticals	-$129.47M	-$1.98	N/A	N/A	N/A	N/A	-42.58%	-38.65%	N/A

Latest MIST, ABEO, OLMA, and ALDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ABEO Abeona Therapeutics	-$0.39	$1.71	+$2.10	$1.71	$21.71 million	$0.40 million
8/12/2025	Q2 2025	MIST Milestone Pharmaceuticals	-$0.18	-$0.20	-$0.02	-$0.20	N/A	N/A
8/11/2025	Q2 2025	OLMA Olema Pharmaceuticals	-$0.43	-$0.51	-$0.08	-$0.51	N/A	N/A
8/7/2025	Q2 2025	ALDX Aldeyra Therapeutics	-$0.21	-$0.16	+$0.05	-$0.16	$1.08 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.09	6.73	4.90
ALDX Aldeyra Therapeutics	N/A	2.86	2.86
MIST Milestone Pharmaceuticals	4.06	4.97	4.97
OLMA Olema Pharmaceuticals	0.01	11.09	11.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
ALDX Aldeyra Therapeutics	59.71%
MIST Milestone Pharmaceuticals	86.18%
OLMA Olema Pharmaceuticals	91.78%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	6.90%
ALDX Aldeyra Therapeutics	9.60%
MIST Milestone Pharmaceuticals	19.50%
OLMA Olema Pharmaceuticals	16.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	51.28 million	47.74 million	Optionable
ALDX Aldeyra Therapeutics	10	59.90 million	54.15 million	Optionable
MIST Milestone Pharmaceuticals	30	84.99 million	43.04 million	Optionable
OLMA Olema Pharmaceuticals	70	68.63 million	57.41 million	Optionable

MIST, ABEO, OLMA, and ALDX Headlines

Recent News About These Companies

Olema Oncology to Participate in Upcoming Investor Conferences

August 20 at 4:30 PM | globenewswire.com

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 20 at 2:27 AM | americanbankingnews.com

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 17, 2025 | marketbeat.com

Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

August 16, 2025 | marketbeat.com

Olema Pharmaceuticals (NASDAQ:OLMA) Given New $29.00 Price Target at JPMorgan Chase & Co.

August 15, 2025 | americanbankingnews.com

Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Raised to $21.00

August 14, 2025 | americanbankingnews.com

Citigroup Forecasts Strong Price Appreciation for Olema Pharmaceuticals (NASDAQ:OLMA) Stock

August 13, 2025 | marketbeat.com

Olema Pharmaceuticals (NASDAQ:OLMA) Posts Earnings Results

August 12, 2025 | marketbeat.com

Olema Oncology Reports Second Quarter 2025 Financial and Operating Results

August 11, 2025 | globenewswire.com

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 4, 2025 | globenewswire.com

Olema Pharmaceuticals (OLMA) Expected to Announce Earnings on Tuesday

July 29, 2025 | marketbeat.com

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 2, 2025 | globenewswire.com

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

H.C. Wainwright Backs Olema Pharmaceuticals (OLMA) as Phase 3 Trials Advance

May 30, 2025 | msn.com

Olema Pharmaceuticals Selects 90 mg Palazestrant Dose for Phase 3 OPERA-01 and OPERA-02 Trials

May 29, 2025 | nasdaq.com

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

May 28, 2025 | globenewswire.com

Olema Oncology to Participate in Upcoming Investor Conferences

May 21, 2025 | globenewswire.com

Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?

May 21, 2025 | zacks.com

Olema Oncology Reports First Quarter 2025 Financial and Operating Results

May 13, 2025 | globenewswire.com

What Role Might (NASDAQ:OLMA) Play in the Changing Landscape of the...

May 12, 2025 | kalkinemedia.comK

Olema Oncology to Participate in Upcoming Investor Conferences

May 9, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MIST, ABEO, OLMA, and ALDX Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$7.23 +0.12 (+1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$7.21 -0.02 (-0.28%)

As of 07:53 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Aldeyra Therapeutics NASDAQ:ALDX

$5.81 -0.07 (-1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$5.81 0.00 (0.00%)

As of 07:58 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Milestone Pharmaceuticals NASDAQ:MIST

$1.70 -0.01 (-0.58%)

Closing price 04:00 PM Eastern

Extended Trading

$1.70 0.00 (0.00%)

As of 07:59 PM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Olema Pharmaceuticals NASDAQ:OLMA

$5.76 +0.22 (+3.97%)

Closing price 04:00 PM Eastern

Extended Trading

$5.76 0.00 (-0.09%)

As of 04:10 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time